J&J reports $100M in sales of COVID-19 vaccine
Health care giant Johnson & Johnson reported strong first-quarter numbers, boosted by sales of its one-dose COVID-19 vaccine — despite the shot currently being on pause in the United States. J&J reported a first-quarter net income of $6.2 billion ($2.32 per share), which included $100 million from sales of the COVID-19 vaccine, according to the...